Press "Enter" to skip to content

Lupin gets USFDA nod for myelodysplastic syndrom drug

The company has received an approval from the United States Food and Drug Administration (USFDA) to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement.

Original source: https://health.economictimes.indiatimes.com/news/pharma/lupin-gets-usfda-nod-for-myelodysplastic-syndrom-drug/66634579?utm_source=RSS&utm_medium=ETRSS

Also Read:   Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir